Case Report Explores Caplacizumab in Late-Diagnosed Congenital Thrombotic Thrombocytopenic Purpura

A newly published clinical case report details the rapid hematologic improvement and subsequent disease course of a 74-year-old patient with congenital thrombotic thrombocytopenic purpura who received the anti-von Willebrand factor nanobody caplacizumab in combination with plasma exchange and corticosteroid therapy. Reporting in Frontiers in Hematology, a clinical team led by

Read More »

Space →